Project Grant R44HG012534
Award Date
6/13/22
Completion Date
5/31/25
Dollars Obligated
$3.3M
Federal Agency
National Human Genome Research Institute
Federal Grant Program
93.172
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This Project Grant award of $350,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop innovative technology capable of high-accuracy sequencing of the RNA modifications pseudouridine (Ψ) and N6-methyladenosine (m6A). The project is a collaborative effort between academia and industry, led by Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The key objectives are...
This federal Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), aims to develop SPINSEQ, an innovative RNA sequencing platform that can accurately detect and quantify critical RNA modifications. The $383,482 award, granted on June 6, 2025, will fund the Phase I development and optimization of the SPINSEQ technology, which seeks to overcome the limitations of existing RNA sequencing methods by preserving RNA...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research federal grant program (CFDA 93.172), will provide $215,088 to Directseq Biosciences, Inc. to develop an exhaustive de novo RNA sequencing method using next-generation mass spectrometry (NGMS-seq). The objective is to create a technology that can directly identify and sequence every RNA species in a sample, while also comprehensively profiling all RNA modifications, without bias....
The Alida Biosciences Inc. was awarded a $765,105 Project Grant from the National Institutes of Health National Human Genome Research Institute under the Human Genome Research federal grant program (CFDA 93.172) on August 17, 2021 to complete work by February 28, 2022. The grant funds the development of a new approach to analyze RNA modifications across entire transcriptomes in a multiplexed reaction at near single-base resolution. Currently available methods either lack sequence context or...
This federal Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research CFDA program (93.172), provides $406,500 to Directseq Biosciences, Inc. to advance next-generation mass spectrometry-based sequencing (NGMS-SEQ) methods. The primary objectives are to 1) develop high-throughput NGMS-SEQ techniques for direct sequencing of transfer RNA (tRNA) samples, including physiologically relevant ones, and 2) enhance technologies to quantitatively...
This $397,599 Project Grant awarded by the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) supports the development of a novel epigenetic analysis method by Xgenomes Corp. The project aims to build out Xgenomes' single-molecule platform that can determine DNA methylation status with unprecedented accuracy, overcoming limitations of existing sequencing-based approaches. Specifically, the project will optimize the chemistry and buffer composition of the probe library...
This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...
This Project Grant award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), provides $2,078,214 to Precision Epigenomics Inc., a University of Arizona spin-out company, to conduct a multi-site clinical validation study for their "Sentinel-MPE" liquid biopsy assay. The aim is to establish the diagnostic value of this test to identify cancer in pleural effusions and validate its use for cancer...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), provides $1,020,280 to Vellum Biotechnology, Inc. to develop a new nucleic acid extraction technology to enable high-quality DNA sequencing from formalin-fixed, paraffin-embedded tissue (FFPET) samples. The technology, called epitachophoresis (ETP), aims to improve the yield, quality, and length of purified nucleic acids extracted from challenging FFPET...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...